Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Change in Account Payables (2024 - 2025)

Caris Life Sciences has reported Change in Account Payables over the past 2 years, most recently at $12.2 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $12.2 million for Q4 2025, up 331.65% from a year ago — trailing twelve months through Dec 2025 was $10.1 million (changed N/A YoY), and the annual figure for FY2025 was $11.0 million, up 4982.74%.
  • Change in Account Payables for Q4 2025 was $12.2 million at Caris Life Sciences, up from $729000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for CAI hit a ceiling of $12.2 million in Q4 2025 and a floor of -$5.3 million in Q4 2024.